If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

On a video call in early September, Sarah Tabrizi first saw the data that she and other researchers studying Huntington’s ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.